Market Exclusive

JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Entry into a Material Definitive Agreement

JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry into a Material Definitive Agreement.

As previously reported, on November22, 2016, Jaguar Animal Health,Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors to which the Company agreed, among other things, to issue warrants to purchase up to an aggregate of 1,666,668 shares of Common Stock at an exercise price of $1.00 per share (the “SeriesC Warrants”).

On July31, 2017, the Company entered into Warrant Exercise Agreements (the “Exercise Agreements”) with certain holders of the SeriesC Warrants (the “Exercising Holders”), which Exercising Holders own, in the aggregate, SeriesC Warrants exercisable for 908,334 shares of Common Stock. to the Exercise Agreements, the Exercising Holders and the Company agreed that the Exercising Holders would exercise their SeriesC Warrants with respect to 908,334 shares of Common Stock underlying such SeriesC Warrants for a reduced exercise price equal to $0.40 per share.

The Company expects to receive aggregate gross proceeds of approximately $363,333.60 from the exercise of the SeriesC Warrants by the Exercising Holders.

The description of terms and conditions of the Exercise Agreements set forth herein do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Exercise Agreement, which is attached hereto as Exhibit10.1.

Item 3.03 Material Modifications to Rights of Security Holders.

The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.03.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.

Description

10.1

Formof Warrant Exercise Agreement

Jaguar Animal Health, Inc. ExhibitEX-10.1 2 a17-18619_2ex10d1.htm EX-10.1 Exhibit 10.1   [JAGUAR LETTERHEAD]   July 31,…To view the full exhibit click here
About JAGUAR ANIMAL HEALTH,INC. (NASDAQ:JAGX)
Jaguar Animal Health, Inc. is an animal health company focused on developing and commercializing gastrointestinal products for companion and production animals, and horses. The Company is developing a formulation of a Croton lechleri product for the treatment of ulcers in horses. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products. Its pipeline includes prescription drug product candidates for over nine indications across various species and non-prescription products targeting approximately seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Virend, Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm. Canalevia is its lead prescription drug product candidate for the treatment of various forms of diarrhea in dogs. Neonorm Calf and Neonorm Foal are its lead non-prescription products to improve gut health and normalize stool formation.

Exit mobile version